Development of a Type IIs Cloning Strategy and Subsequent Production of Monoclonal Antibodies from PCR Amplification, Donor Vectors & Synthesized DNA Fragments
Alongside the emerging field of immunotherapy, with monoclonal antibody drugs at the forefront, radically reshaping medicine, the need for process and technology improvements that can lower drug development costs and bring better drugs to the market faster is increasing. One such process improvement being fast and efficient cloning strategies which enable moving into high-throughput formats. Tradi